SCHEMBL905747

SCHEMBL905747

CCCCNC(=N)CCCC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.43
ACHE P22303 7/20 0.40
CASP2 P42575 1/20 0.40
MMP2 P08253 1/20 0.40
CNR1 P21554 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
EPHX2 P34913 1/20 0.38
NAAA Q02083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11588184 0.91 EPHX1 (0.50) EPHX1CASP2EPHX2NAAA
SCHEMBL9281657 0.88 CASP2 (0.48) EPHX1CASP2EPHX2NAAA
SCHEMBL13488631 0.84 CASP2 (0.32) EPHX1CASP2EPHX2NAAA
SCHEMBL25458480 0.83 EPHX1 (0.45) EPHX1CASP2CNR1EPHX2
SCHEMBL12523204 0.82 TSHR (0.35) EPHX1CASP2
SCHEMBL14479171 0.82
SCHEMBL10981737 0.82
SCHEMBL26751913 0.81 CASP2 (0.57) EPHX1CASP2NAAA
SCHEMBL23009850 0.81 EPHX1 (0.48) EPHX1CASP2CNR1EPHX2
SCHEMBL13864338 0.81 CASP2 (0.42) EPHX1CASP2EPHX2NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES FROEHLER BRIAN (US) 2004-12-30 US claimed
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines FROEHLER BRIAN (US) 2003-09-11 US claimed
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines ISIS PHARMACEUTICALS, INC. 2003-05-22 US claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO disclosed
EP-4740010-A1 NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY Agilent Technologies, Inc. (US) 2026-05-13 EP disclosed
EP-4649170-A1 NUCLEOTIDE EXTENSION CHAIN VERIFICATION Agilent Technologies, Inc. (US) 2025-11-19 EP disclosed
US-12453779-B2 Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates FORSCHUNGSVERBUND BERLIN E.V. (DE) 2025-10-28 US disclosed
US-20250197439-A1 DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY-NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY-NUCLEOTIDE DICERNA PHARMACEUTICALS, INC. (US) 2025-06-19 US disclosed
WO-2025106093-A1 PURIFICATION METHODS FOR OLIGONUCLEOTIDES YIELDING PURIFIED OLIGONUCLEOTIDES WITH 5'-TERMINAL PHOSPHATE GROUPS AGILENT TECHNOLOGIES, INC. (US) 2025-05-22 WO disclosed
WO-2025072232-A1 PHOSPHONATE PRODRUGS AND USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2025-04-03 WO disclosed
US-20250090672-A1 CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES FORSCHUNGSVERBUND BERLIN EV (DE) 2025-03-20 US disclosed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO disclosed
US-5118800-A Oligonucleotides possessing a primary amino group in the terminal nucleotide CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5118802-A DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1992-06-02 US disclosed
US-5015733-A Phosphoramidites and oligonucleotides derived therefrom CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1991-05-14 US disclosed
US-4849513-A Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1989-07-18 US disclosed
EP-0270651-A4 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1989-03-29 EP disclosed
EP-0270651-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. CALIFORNIA INST OF TECHN (US) 1988-06-15 EP disclosed
WO-1988000201-A1 NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) 1988-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 EPHX1 625/4885ACHE 4753/4885CASP2 4572/4885
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES NUDT1, DHX15, DDX5 EPHX1 625/4885ACHE 4753/4885CASP2 4572/4885
US-20250197439-A1 DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY-NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY-NUCLEOTIDE ME3, POLRMT, NSUN3 EPHX1 3609/4885ACHE 1371/4885CASP2 3824/4885
US-12453779-B2 Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates ACP1, PTMS, ALG1 EPHX1 3960/4885ACHE 3061/4885CASP2 4738/4885
US-20250090672-A1 CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES PFAS, PHOSPHO1, PNKP EPHX1 1517/4885ACHE 2503/4885CASP2 4518/4885
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 EPHX1 625/4885ACHE 4753/4885CASP2 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.